These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 19258384)

  • 1. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
    Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
    Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatible peritoneal dialysis solution preserves residual renal function.
    Kim S; Oh KH; Oh J; Kim SJ; Chung W; Song YR; Na KY; Oh YK; Ahn C; Kim SG; Tan KC
    Am J Nephrol; 2012; 36(4):305-16. PubMed ID: 23007025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
    Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function.
    Wang AY; Woo J; Wang M; Sea MM; Sanderson JE; Lui SF; Li PK
    Nephrol Dial Transplant; 2005 Feb; 20(2):396-403. PubMed ID: 15187196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).
    Kim SG; Kim S; Hwang YH; Kim K; Oh JE; Chung W; Oh KH; Kim HJ; Ahn C;
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S117-22. PubMed ID: 18552239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis.
    Maksic D; Vasilijic S; Colic M; Stankovic-Popovic V; Bokonjic D
    Adv Perit Dial; 2009; 25():50-5. PubMed ID: 19886317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and intraperitoneal proinflammatory cytokines profiles in patients on chronic peritoneal dialysis.
    Maksić D; Colić M; Stanković-Popović V; Radojević M; Bokonjić D
    Med Pregl; 2007; 60 Suppl 2():53-7. PubMed ID: 18928158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of peritoneal dialysis method on residual renal function in children.
    Roszkowska-Blaim M; Skrzypczyk P; Jander A; Tkaczyk M; Bałasz-Chmielewska I; Zurowska A; Drozdz D; Pietrzyk JA
    Adv Perit Dial; 2012; 28():112-9. PubMed ID: 23311226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
    Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual renal function in children treated with continuous ambulatory peritoneal dialysis or automated peritoneal dialysis--a preliminary study.
    Roszkowska-Blaim M; Skrzypczyk P; Drozdz D; Pietrzyk JA
    Adv Perit Dial; 2009; 25():103-9. PubMed ID: 19886329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis.
    Szeto CC; Lai KN; Wong TY; Law MC; Leung CB; Yu AW; Li PK
    Am J Kidney Dis; 1999 Dec; 34(6):1056-64. PubMed ID: 10585315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
    Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental dialysis with automated peritoneal dialysis.
    Neri L; Viglino G; Cappelletti A; Gandolfo C; Barbieri S
    Adv Perit Dial; 2003; 19():93-6. PubMed ID: 14763041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
    Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
    Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study.
    Dittrich E; Puttinger H; Schillinger M; Lang I; Stefenelli T; Hörl WH; Vychytil A
    Nephrol Dial Transplant; 2006 May; 21(5):1334-9. PubMed ID: 16046499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
    Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
    Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.